European Journal of Cancer
Volume 45, Issue 17 , Pages 2984-2991 , November 2009

What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?

  • Matti Aapro

      Affiliations

    • Institut Multidisciplinaire d’Oncologie, Clinique de Genolier, CH-1272 Genolier, Switzerland
    • Corresponding Author InformationCorresponding author: Tel.: +41 (22) 366 91 06; fax: +41 (22) 366 91 31.
    • ,
  • Agustí Barnadas

      Affiliations

    • Hospital de Sant Pau, Barcelona, Spain
    • ,
  • Robert C. Leonard

      Affiliations

    • Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, UK
    • ,
  • Maurizio Marangolo

      Affiliations

    • Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy
    • ,
  • Michael Untch

      Affiliations

    • Helios Klinikum, Berlin Buch, Germany
    • ,
  • Lidia Ukarma

      Affiliations

    • Hoffmann-La Roche Ltd., Basel, Switzerland
    • ,
  • Hans-Ulrich Burger

      Affiliations

    • Hoffmann-La Roche Ltd., Basel, Switzerland
    • ,
  • Armin Scherhag

      Affiliations

    • Hoffmann-La Roche Ltd., Basel, Switzerland
    • I. Medical Clinic, University Hospital Mannheim, University of Heidelberg, Germany
    • ,
  • Bruno Osterwalder

      Affiliations

    • Hoffmann-La Roche Ltd., Basel, Switzerland

Received 18 September 2008 ,Revised 5 June 2009 ,Accepted 26 June 2009.

References 

  1. Trousseau A. Phlegmasia alba dolens. In:  Balliere J editors. Clinique médicale de l’Hôtel-Dieu Paris. 2nd ed.. Paris, France: JB Balliere & Fils; 1865;p. 654–712
  2. Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8:381–388
  3. Lee AY, Levine MN. Venous thromboemobolism and cancer: risk and outcomes. Circulation. 2003;107(Suppl. 1):117–121
  4. Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003;349:109–111
  5. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch Intern Med. 2000;160:809–815
  6. Remiszewski P, Slodkowska J, Wiatr E, et al. Pulmonary thromboembolism as the main or secondary cause of death in patients treated for small cell lung cancer. Pneumonol Alerfol Pol. 1999;67:470–476
  7. Gezelius C, Eriksson A. Neoplastic disease in a medicolegal autopsy material. A retrospective study in northern Sweden. Rechtsmed. 1988;101:115–130
  8. Ambrus JL, Ambrus CM, Mink IB, Pickern JW. Causes of death in cancer patients. J Med. 1975;6:61–64
  9. Gao S, Escalante C. Venous thromboembolism and malignancy. Expert Rev Anticancer Ther. 2004;4(2):303–319
  10. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388
  11. Gail MH, Costantino JP, Bryant J, et al. Weighing the risk and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829–1846
  12. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in woman with stage II breasts cancer. N Engl J Med. 1988;318(7):, 404–407
  13. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 1984;54(7):1264–1268
  14. Coiffier B, Boogaerts M, Aapro M, Hayward C, Burger H-U. Effect of treatment with epoetin beta on thromboembolic events in anemic patients with cancer: a meta-analysis. Support Cancer Ther. 2006;4(1):49–55
  15. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Exporting Alfa Study Group. J Clin Oncol. 2001;19:2865–2874
  16. Vansteenkiste J, Pirker R, Massuti B, Barata F, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211–1220
  17. Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-β on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer. 2008;99:14–22
  18. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anaemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960–5972
  19. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage. 2004;27:185–190
  20. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–924
  21. Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. The Oncologist. 2008;13(3):11–15
  22. Bohlius J, Wilson J, Seidenfeld S, et al. Erythropoietin or darbepoetin for patients with (cochrane review). In: The cochrane library, issue 3. Chichester, UK: John & Sons Ltd.; 2006.
  23. van Doormaal FF, Büller HR, Middeldorp S. Development in antithrombotic therapy. Crit Rev Oncol Hematol. 2008;66(2):145–154
  24. Niers TM, Klerk CP, DiNisio M, et al. Mechanism of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol. 2007;61(3):195–207
  25. Aapro M, Leonard RC, Barnadas A, et al. Effect of once – weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline – and/or taxane-based chemotherapy: results of the breast cancer-anemia and the value of erythropoietin (BRAVE) study. J Clin Oncol. 2008;26(4):592–598
  26. Pober JS. TNF as an activator of vascular endothelium. Ann Inst Pasteur Immunol. 1988;139(3):317–323
  27. Dvorak HF. Thrombosis and cancer. Hum Pathol. 1987;18(3):275–284
  28. Tang Y-D, Rinder HM, Katz SD. Effects of recombinant human erythropietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial. Am Heart J. 2007;154:494.e1–494.e7
  29. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983–2989
  30. Fullmer AC, Miller R. Retrospective review of hemoglobin and/or hematocrit levels with occurrence of thrombosis in cancer patients treated with erythropoiesis stimulating agents. J Oncol Pharm Pract. 2009;00:1–7

PII: S0959-8049(09)00512-7

doi: 10.1016/j.ejca.2009.06.031

European Journal of Cancer
Volume 45, Issue 17 , Pages 2984-2991 , November 2009

Article Tools

* Image Usage & Resolution